Parexel announced the acquisition of Vitrana, a provider of an AI-enabled, end-to-end pharmacovigilance (PV) technology platform that supports patient safety and drug safety operations. Financial terms of the transaction were not disclosed. According to Parexel, the acquisition adds new technology capabilities to its patient safety solutions and broadens its ability to serve life sciences customers with integrated clinical and consulting services.
Vitrana’s platform uses intelligent automation and artificial intelligence to accelerate end-to-end patient safety and PV processes, support first-time quality, and enhance regulatory compliance. The technology is system-agnostic and can integrate with any safety database, enabling customers to deploy specific capabilities based on their requirements and helping improve accuracy, cycle times, and operational efficiency. Parexel stated that the deal aligns with its broader investment in AI-enabled solutions across clinical development, spanning regulatory submissions, trial execution, and now patient safety.
Vitrana’s team and technology will be aligned with Parexel’s Patient Safety Services organization. During a transition period, the business will operate under the name “Vitrana – a Parexel Company,” with phased integration planned in line with existing customer commitments and Vitrana’s product roadmap milestones.